Aptose Biosciences (NASDAQ:APTO) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report released on Friday morning. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $2.00 price target on shares of Aptose Biosciences in a research note on Friday, January 10th.

Aptose Biosciences Price Performance

Shares of NASDAQ:APTO opened at $0.21 on Friday. The company has a market capitalization of $12.82 million, a PE ratio of -0.07 and a beta of 0.87. Aptose Biosciences has a 1 year low of $0.13 and a 1 year high of $2.20. The business has a fifty day moving average price of $0.22 and a two-hundred day moving average price of $0.37.

Hedge Funds Weigh In On Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp raised its holdings in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 401,750 shares of the biotechnology company’s stock after buying an additional 167,282 shares during the quarter. Sigma Planning Corp owned about 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.